These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 17175308

  • 1. Proteinuria after conversion to sirolimus in renal transplant recipients.
    Sahin GM, Sahin S, Kantarci G, Ergin H.
    Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
    [Abstract] [Full Text] [Related]

  • 2. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 3. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Sep; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 4. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
    Boratyńska M, Banasik M, Watorek E, Falkiewicz K, Patrzałek D, Szyber P, Klinger M.
    Transplant Proc; 2006 Sep; 38(1):101-4. PubMed ID: 16504675
    [Abstract] [Full Text] [Related]

  • 5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the efficacy and safety of conversion to sirolimus in 85 renal transplant recipients.
    Sola E, Lopez V, Gutierrez C, Cabello M, Burgos D, Gonzalez Molina M, Hernandez D.
    Transplant Proc; 2009 Nov; 41(6):2137-8. PubMed ID: 19715855
    [Abstract] [Full Text] [Related]

  • 7. Proteinuria in transplant patients associated with sirolimus.
    Franco AF, Martini D, Abensur H, Noronha IL.
    Transplant Proc; 2007 Mar; 39(2):449-52. PubMed ID: 17362756
    [Abstract] [Full Text] [Related]

  • 8. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA, Al-Otaibi T, Johny KV, Hamid MH, Al-Waheeb S, Hasaneen H, Awadain WH, Nawas KM, El-Sayed A, Said T, Nair MP, Nampoory MR.
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [Abstract] [Full Text] [Related]

  • 9. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
    Gutiérrez MJ, González E, Andrés A, Morales JM.
    Transplant Proc; 2009 Sep; 41(6):2348-50. PubMed ID: 19715916
    [Abstract] [Full Text] [Related]

  • 10. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B, Caliskan Y, Ozkan O, Gorgulu N, Yazici H, Turkmen A, Sever MS.
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [Abstract] [Full Text] [Related]

  • 11. Sirolimus in chronic allograft nephropathy in pediatric recipients.
    Ibáñez JP, Monteverde ML, Diaz MA, Goldberg J, Turconi AF.
    Pediatr Transplant; 2007 Nov; 11(7):777-80. PubMed ID: 17910656
    [Abstract] [Full Text] [Related]

  • 12. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

  • 13. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study.
    Ruiz JC, Diekmann F, Campistol JM, Sanchez-Fructuoso A, Rivera C, Oliver J, Fernandez-Fresnedo G, Arias M.
    Transplant Proc; 2005 Nov; 37(9):3833-5. PubMed ID: 16386555
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma.
    Gutiérrez-Dalmau A, Sánchez-Fructuoso A, Sanz-Guajardo A, Mazuecos A, Franco A, Rial MC, Iranzo P, Torregrosa JV, Oppenheimer F, Campistol JM.
    Transplant Proc; 2005 Nov; 37(9):3836-8. PubMed ID: 16386556
    [Abstract] [Full Text] [Related]

  • 15. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 16. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C.
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [Abstract] [Full Text] [Related]

  • 17. Conversion to sirolimus allows preservation of renal function in kidney and kidney-pancreas allograft recipients.
    Laham G, Sleiman S, Soler Pujol G, Diaz C, Dávalos M, Vilches A.
    Transplant Proc; 2010 Jun; 42(1):309-13. PubMed ID: 20172338
    [Abstract] [Full Text] [Related]

  • 18. Conversion to sirolimus in posttransplant renal neoplasms.
    Lopez V, Gutierrez C, Cabello M, Burgos D, Sola E, Gonzalez-Molina M.
    Transplant Proc; 2007 Sep; 39(7):2264-6. PubMed ID: 17889158
    [Abstract] [Full Text] [Related]

  • 19. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 20. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
    Ruiz JC, Campistol JM, Sánchez-Fructuoso A, Rivera C, Oliver J, Ramos D, Campos B, Arias M, Diekmann F.
    Nephrol Dial Transplant; 2006 Nov 27; 21(11):3252-7. PubMed ID: 16954170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.